Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Feature

A biogeneric company leads the field of next generation human growth hormone (hGH)

Posted on: 24 Oct 05
A biogeneric company leads the field of next generation human growth hormone (hGH)

Summary

After Genentech had to terminate commercializtion of its Nutropin Depot preparation, the field now is lead by Korea-based LG Life Science and its European licensee BioPartners with the slow release formulation of hGH (LB03002)

The global hGH market of US$ 2.2 bln in 2004 is not endangered by the only three biogeneric competitors in regulated countries, but by next generation developments of more convenient administration regimens and forms. After Genentech had to terminate commercializtion of its Nutropin Depot preparation, the field now is lead by Korea-based LG Life Science and its European licensee BioPartners with the slow release formulation of hGH (LB03002) which received FDA clearance to initiate phase III studies. Current market leaders Pfizer (33 % market share), Eli Lilly (19.4 %), Novo Nordisk (16.8 %), Genentech (16 %) and Serono (12.1 %) only have early stage R&D projects with next generation formulations. These results were found in a search conducted by La Merie Business Intelligence. The results were published in the October 24 issue of R&D Pipeline News , edited by La Merie.


 


The first biogeneric hGH preparation (Omnitrope) from Sandoz (Novartis) is cleared for sale in Australia and received position opinions from European and US regulators, but marketing clearance so far was not granted, although basic hGH patents already expired.  LG Life Science submitted the marketing application for its yeast produced hGH already in June 2004 to the EMEA. Canadian Cangene and partners Apotex and BioGeneriX are still in phase III trials.


 


All first generation and biogeneric hGH preparations so far require daily parenteral administration which is inconvenient for the patient. Less frequent administration and pain-avoiding needle-free delivery systems would constitute a real advantage. Ongoing R&D projects concentrate on slow-release and long-acting hGH molecules as well as on oral and pulmonary delivery systems. Transdermal and intranasal systems are also offered by the drug delivery industry, whereas low cost production in transgenic cows or aquatic plants still is in its infancy. The number of hGH manufacturing companies in countries without patent protection and, therefore, potential biogeneric producers, is small despite a continuosly growing market due to life cycle management measures and label extensions.


 


 



About La Merie


 


La Merie S.L. is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com .


 


About R&D Pipeline News


 


R&D Pipeline News is a premier information source about research and development projects in the pipeline of the biopharmaceutical industry and is directed to all stakeholders in R&D. The weekly publication comes in a rapid- and easy-to-screen tabular format and provides access to the original information source via hyperlinks. R&D Pipeline News covers all relevant treatment modalities and is directly delivered to the desktop via e-mail.


More information about the journal, a free trial and subscriptions are available via the website, www.lamerie.com.

La Merie Business Intelligence Press Release

Last updated on: 27/08/2010 11:40:18

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.